NeoGenomics Inc. (NASDAQ:NEO) insider Maher Albitar sold 105,300 shares of the firm’s stock in a transaction dated Tuesday, September 20th. The stock was sold at an average price of $8.20, for a total value of $863,460.00. Following the completion of the sale, the insider now directly owns 105,300 shares of the company’s stock, valued at approximately $863,460. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Maher Albitar also recently made the following trade(s):

  • On Monday, September 12th, Maher Albitar sold 60,075 shares of NeoGenomics stock. The stock was sold at an average price of $8.23, for a total value of $494,417.25.
  • On Friday, August 19th, Maher Albitar sold 370,000 shares of NeoGenomics stock. The stock was sold at an average price of $8.23, for a total value of $3,045,100.00.

NeoGenomics Inc. (NASDAQ:NEO) opened at 8.25 on Friday. NeoGenomics Inc. has a 12 month low of $5.49 and a 12 month high of $9.54. The stock’s market capitalization is $642.62 million. The company’s 50-day moving average price is $8.10 and its 200 day moving average price is $8.00.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, July 26th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.01. The business earned $63.10 million during the quarter, compared to analysts’ expectations of $61.07 million. NeoGenomics had a positive return on equity of 3.18% and a negative net margin of 3.76%. The business’s quarterly revenue was up 159.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.01 EPS. On average, analysts forecast that NeoGenomics Inc. will post $0.13 earnings per share for the current fiscal year.

NEO has been the subject of several research analyst reports. Raymond James Financial Inc. initiated coverage on NeoGenomics in a research note on Thursday, September 8th. They issued an “outperform” rating and a $10.00 price objective for the company. Zacks Investment Research upgraded NeoGenomics from a “hold” rating to a “buy” rating and set a $9.25 price objective for the company in a research note on Friday, August 5th. BTIG Research restated a “buy” rating and issued a $10.00 price objective on shares of NeoGenomics in a research note on Friday, July 8th. Benchmark Co. raised their price objective on NeoGenomics from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, July 27th. Finally, Craig Hallum restated a “buy” rating on shares of NeoGenomics in a research note on Saturday, July 9th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $10.32.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NEO. Cubist Systematic Strategies LLC boosted its position in NeoGenomics by 189.1% in the second quarter. Cubist Systematic Strategies LLC now owns 50,955 shares of the company’s stock valued at $410,000 after buying an additional 33,329 shares in the last quarter. Panagora Asset Management Inc. boosted its position in NeoGenomics by 43.6% in the second quarter. Panagora Asset Management Inc. now owns 37,475 shares of the company’s stock valued at $301,000 after buying an additional 11,373 shares in the last quarter. Kopp Investment Advisors LLC boosted its position in NeoGenomics by 3.4% in the second quarter. Kopp Investment Advisors LLC now owns 1,476,902 shares of the company’s stock valued at $11,875,000 after buying an additional 48,354 shares in the last quarter. A.R.T. Advisors LLC boosted its position in NeoGenomics by 62.9% in the second quarter. A.R.T. Advisors LLC now owns 49,185 shares of the company’s stock valued at $395,000 after buying an additional 19,000 shares in the last quarter. Finally, Guggenheim Capital LLC boosted its position in NeoGenomics by 19.5% in the second quarter. Guggenheim Capital LLC now owns 27,529 shares of the company’s stock valued at $222,000 after buying an additional 4,488 shares in the last quarter. 77.20% of the stock is owned by institutional investors and hedge funds.

NeoGenomics Company Profile

5 Day Chart for NASDAQ:NEO

Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.